Claim Details

View detailed information about this claim and its related sources.

Back to Claims

Claim Information

Complete details about this extracted claim.

Claim Text
One treatment, daraxonrasib, which just received approval from the Food and Drug Administration, doubled life expectancy in a clinical trial of patients who had previously been treated with chemotherapy for metastatic pancreatic cancer, giving them more than 13 months to live, compared to fewer than seven months for those who received chemotherapy.
Simplified Text
The drug daraxonrasib, recently approved by the FDA, doubled life expectancy to over 13 months for certain metastatic pancreatic cancer patients in a clinical trial, compared to under 7 months for those on chemotherapy.
Confidence Score
1.000
Claim Maker
The author
Context Type
News Article
Context Details
{
    "outcome": "doubled life expectancy (>13 months vs <7 months)",
    "drug_name": "daraxonrasib",
    "patient_group": "metastatic pancreatic cancer patients previously treated with chemotherapy",
    "approving_body": "Food and Drug Administration"
}
Subject Tags
Health Science Medicine
UUID
5e4d350a-2c06-48dd-af28-db58466b0d25
Vector Index
āœ— No vector
Created
September 18, 2026 at 2:04 AM (3 weeks ago)
Last Updated
September 18, 2026 at 2:04 AM (3 weeks ago)

Original Sources for this Claim (1)

All source submissions that originally contained this claim.

Screenshot of https://nytimes.com/2026/09/17/well/pancreatic-cancer-family-genetic-risk.html
I Lost 3 Brothers to Cancer. Iā€™m Determined Not to Be Next.
Completed News
30 claims šŸ”„
3 weeks ago
https://nytimes.com/2026/09/17/well/pancreatic-cancer-family-genetic-risk.html

A journalist recounts losing three brothers to pancreatic cancer and his journey to get tested and monitored for the disease. He shares insights into the challenges of early detection and new treatment advancements.

Pancreatic Cancer Family History Genetic Testing Cancer Screening Health Monitoring Medical Research

Similar Claims (5)

Other claims identified as semantically similar to this one.